Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Hospital, Montpellier
Methods :
One hundred patients with a metastatic prostate cancer will be recruited plus 50 healthy donors. Twenty ml of blood will be drawn : 10 ml of blood will be drawn on CellSave tubes (fixed cells) for CTC detection using the FDA-cleared CellSearch system (gold standard) and 10 ml of blood will be drawn on EDTA tubes (viable cells) for the detection of functional CTCs using the EPIDROP. Patients will be followed for 18 months.
Samples from fifty control subjects will be provided by the Etablissement Français du Sang.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
To be male, over 18 years old
Metastatic prostate cancer naive to any treatment or metastatic prostate cancer in biological recurrence (PSA increase) and/or clinical recurrence after hormone suppression (mCRPC)
You may not be if
Non-metastatic prostate cancer in biological and/or clinical recurrence after hormone-suppression (nmCRPC)
Other active or treated cancer less than 5 years old
Be protected by law (guardianship or curatorship)
Be deprived of liberty by administrative decision
Not being affiliated to a social security scheme, or not being a beneficiary of such a plan
Being in a period of exclusion from another protocol
Inability to understand and/or respond to questionnaires
Inability to understand the nature, purpose and methodology of the study
Refusal to sign informed consent
Clareo Health | Detection of Viable CTCs Using the EPIDROP Technology in Metastatic Prostate Cancer (EPIDROP)
